In 261 preterm infants (26–31 weeks) with early RDS on nasal CPAP/NIV, high-dose aerosolised surfactant (APC-0101) did not reduce later instilled liquid surfactant vs control (44.2% vs 50.0%, P=.648). Exploratory low dose: 34.9% (P=.045).
RCTn = 261
Durand et al. Safety and Efficacy of a Novel Aerosolized Surfactant (APC-0101) for the Treatment of Respiratory Distress Syndrome in Preterm Infants: A Randomized Phase 2b Study